Marie Bosslett, Assistant Editor

FDA will review a supplemental New Drug Application for topical roflumilast to treat infant AD with supporting trial data showing rapid itch relief and clear skin gains from week 1.

The FDA has accepted the resubmitted BLA for relabotulinumtoxinA, a next-generation neuromodulator for treating facial lines in adults.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on the approval of dupilumab for pediatric CSU, phase 2b hair growth results with rezpegaldesleukin, multispecific biologics for AD, and more.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of April.

Potential FDA approval of TrenibotE was delayed due to manufacturing-related issues, with no concerns regarding safety, efficacy, or clinical trial data.

At the 2026 Winter Clinical Miami meeting, dermatology leaders emphasized that thriving careers require skills beyond clinical expertise.

Renal transplant patients face frequent warts, fungal infections, and steroid acne, according to new 10-year data.

Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.

New 140-week data show that upadacitinib keeps itch, sleep, and quality-of-life gains steady in patients with moderate to severe atopic dermatitis (AD).

This review of the latest dermatological studies includes insights on minoxidil in onychodystrophy, teleheath outcomes in HS patients, pediatric AD referrals, and more.

AI-analyzed EHRs show a surging burden of hidradenitis suppurativa, chronic urticaria, psoriasis, and eczema, with major comorbidities, costly care, and low biologic use.

Post hoc trial data presented at AAD 2026 show near-clear atopic dermatitis and minimal itch drive bigger gains in quality of life, sleep, mental health, and satisfaction.

Building trust through empathetic communication, education, and support resources is essential to improving outcomes for patients with HS.

Interim investigator-initiated trials reveal how Restylane Skinboosters and Sculptra could improve menopausal skin and address GLP-1 weight-loss volume changes.

REZPEG shows growing hair regrowth at 52 weeks in severe alopecia areata, with favorable safety, hinting at a new biologic alternative to JAKs.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on delgocitinib sNDA for pediatric CHE, new 12-month data for clascoterone 5% in androgenetic alopecia, the rise of GLP-1 usage in dermatology, and more.

Pooled phase 3 data show dupilumab rapidly reduces prurigo nodularis activity, cuts excoriations, and boosts healing by week 24 versus placebo.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

Phase 3 data show clascoterone solution sustains hair regrowth for 12 months with vehicle-like safety, paving the way for a novel male androgenetic alopecia option.

Spatial transcriptomics reveals how UVB phototherapy calms vitiligo skin, silencing IFN-γ pathways and memory T cells to drive repigmentation.

FDA will review LEO Pharma's delgocitinib cream for adolescent patients aged 12-17 with CHE, backed by phase 3 gains and addressing a major treatment gap.

This review of the latest dermatological studies includes insights on the use of microneedling in wound healing, pediatric HS treatment patterns, the role of blood-related phenotypes in hypertrophic scars and keloids, and more.

A new systematic review shows vitiligo’s stigma-driven mental health and quality-of-life burden varies by culture, urging culturally tailored, multidisciplinary care and education.

Take today's poll and explore real-world VHA data showing delayed, low biologic use in chronic spontaneous urticaria, alongside rising ER, inpatient, and outpatient visits after diagnosis.

A rare case shows HAE with chronic spontaneous urticaria; non-itchy facial swelling despite omalizumab signals C4 and C1-INH testing.

In this episode, Daniel Walker, MD, FAAD, explains how GLP-1 drugs may be effective for psoriasis and HS, linking skin inflammation with weight and heart health.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.